Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The user experienced worsening hair loss despite using finasteride and topical minoxidil for two years and is considering oral minoxidil and dutasteride. Suggestions include microneedling, stress management, and alternative treatments like topical finasteride or ketoconazole shampoo.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

An 18-year-old shared his 3-month hair regrowth progress using Kirkland 5% topical minoxidil and a dermaroller, achieving a better hairline without finasteride. He plans to switch from liquid to foam minoxidil for easier styling and is cautious about starting finasteride due to potential hormonal effects.

Finasteride is used for hair loss, with mixed reports of no side effects and claims of long-term negative effects known as Post Finasteride Syndrome (PFS). The conversation debates the existence and causes of PFS, with differing opinions on whether it is psychological or real.

A new hair loss treatment shows promise in mice but is unproven in humans. Effective treatments include finasteride and minoxidil.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The user experienced worsening hair thinning despite using finasteride, minoxidil, and ketoconazole shampoo, and switched to dutasteride five months ago. They are considering adding tretinoin and microneedling to their routine for better results.

Finasteride maintains existing hair, but Minoxidil is less effective on hairlines. Walton Goggins is admired for his receding hairline, possibly using Finasteride and Minoxidil without a hair transplant.

Long-term finasteride use typically slows hair loss, with some users experiencing side effects like sexual dysfunction and depression. Many users also use minoxidil and dutasteride for improved results, though individual responses vary.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Creatine may worsen hair loss in some, especially with androgenic alopecia, but evidence is mixed. Some users experience no hair loss when using creatine with minoxidil and finasteride, while others notice increased shedding.

The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.

A 15-year-old experiencing hair loss and anxiety is using minoxidil and microneedling but is advised against starting finasteride or dutasteride due to age. The discussion emphasizes consulting a doctor, considering hormonal evaluations, and exploring non-medication coping strategies.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

A 38-year-old considering switching from finasteride and minoxidil to dutasteride for hair maintenance, noting past success with finasteride but recent hair shedding. Users shared experiences, with some recommending dutasteride for better regrowth, while others noted potential shedding during the transition.

A 23-year-old shares progress using oral minoxidil and finasteride for hair regrowth, reporting significant improvement in hair density with minimal side effects like initial headaches. The user encourages others with thinning hair to consider these treatments, noting the positive impact on confidence.

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

Nanoxidil may be more effective than Minoxidil for hair loss due to better follicle penetration, but it lacks widespread recognition and research because it's owned by a small company and classified as a cosmetic. The pharmaceutical system favors Minoxidil due to its established market presence and profitability, leaving Nanoxidil largely unstudied and unknown.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The user has been dealing with hair loss for six years using minoxidil, finasteride, and dutasteride without success. They are contemplating shaving their head due to continued hair loss and social anxiety.

Using finasteride and minoxidil for six months led to improved hair density and appearance. A temporary decrease in libido was noted as a side effect.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A user is seeking advice on using finasteride and minoxidil for hair loss after being unhappy with their dermatologist's advice. They are considering getting finasteride on their own due to prescription challenges.

A 22-year-old has been using oral dutasteride and minoxidil for a year to prevent hair loss, experiencing some thinning at the temples but maintaining a full head of hair. The user increased the dosage after consulting a dermatologist and is considering adding ketoconazole shampoo for additional scalp DHT suppression.